Datasets:

bvand086
/

ata_guidelines

Dataset card Data Studio Files Files and versions Community

Split (1)

train · 847 rows

text stringlengths 6 1.29k
include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165:441–446. 543. Pitoia F, Bueno F, Urciuoli C, Abelleira E, Cross G, Tuttle RM 2013 Outcomes of patients with differentiated thyroid cancer risk-stratiﬁed according to the American Thyroid Association and Latin American Thyroid So-ciety risk of recurrence classiﬁcation systems. Thyroid 23:1401–1407. 544. Schvartz C, Bonnetain F, Dabakuyo S, Gauthier M, Cueff A, Fieffe S, Pochart JM, Cochet I, Crevisy E, Dalac A, Papathanassiou D, Toubeau M 2012 Impact on overall survival of radioactive iodine in low-risk differ- entiated thyroid cancer patients. J Clin Endocrinol Metab 97:1526–1535. 545. Durante C, Montesano T, Attard M, Torlontano M, Monzani F, Costante G, Meringolo D, Ferdeghini M, Tumino S, Lamartina L, Paciaroni A, Massa M, Giaco- melli L, Ronga G, Filetti S 2012 Long-term surveillance of papillary thyroid cancer patients who do
not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement? J Clin En- docrinol Metab 97:2748–2753. 546. Kim KM, Park JB, Bae KS, Kim CB, Kang DR, Kang SJ 2013 Clinical prognostic index for recurrence of papil-lary thyroid carcinoma including intraoperative ﬁndings. Endocr J 60:291–297. 547. Ito Y, Kudo T, Kihara M, Takamura Y, Kobayashi K, Miya A, Miyauchi A 2012 Prognosis of low-risk papil- lary thyroid carcinoma patients: its relationship with the size of primary tumors. Endocr J 59:119–125. 548. Lee J, Song Y, Soh EY 2014 Prognostic signiﬁcance of the number of metastatic lymph nodes to stratify the risk of recurrence. World J Surg 38:858–862. 549. Clain JB, Scherl S, Dos RL, Turk A, Wenig BM, Mehra S, Karle WE, Urken ML 2014 Extrathyroidal extension predicts extranodal extension in patients with positive lymph nodes: an important association that may affect clinical management. Thyroid 24:951–957.
550. Riemann B, Kramer JA, Schmid KW, Dralle H, Dietlein M, Schicha H, Sauerland C, Frankewitsch T, Schober O 2010 Risk stratiﬁcation of patients with locally aggres- sive differentiated thyroid cancer. Results of the MSDS trial. Nuklearmedizin 49:79–84. 551. Nixon IJ, Ganly I, Patel S, Palmer FL, Whitcher MM, Tuttle RM, Shaha AR, Shah JP 2011 The impact of microscopic extrathyroid extension on outcome in pa- tients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery 150:1242–1249. 552. Jukkola A, Bloigu R, Ebeling T, Salmela P, Blanco G 2004 Prognostic factors in differentiated thyroid carci- nomas and their implications for current staging classi- ﬁcations. Endocr Relat Cancer 11:571–579. 553. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Ko- bayashi K, Matsuzuka F, Kuma K, Miyauchi A 2006 Prognostic signiﬁcance of extrathyroid extension of papillary thyroid carcinoma: massive but not minimal extension affects the relapse-free survival. World J Surg
30:780–786. 554. Radowsky JS, Howard RS, Burch HB, Stojadinovic A 2014 Impact of degree of extrathyroidal extension of disease on papillary thyroid cancer outcome. Thyroid 24: 241–244. 555. Fukushima M, Ito Y, Hirokawa M, Miya A, Shimizu K, Miyauchi A 2010 Prognostic impact of extrathyroid ex- tension and clinical lymph node metastasis in papillary thyroid carcinoma depend on carcinoma size. World J Surg 34:3007–3014. 556. Baloch ZW, Shaﬁque K, Flannagan M, LiVolsi VA 2010 Encapsulated classic and follicular variants of papillary thyroid carcinoma: comparative clinicopathologic study.Endocr Pract 16:952–959. 557. Deleted. 558. Nishida T, Katayama S, Tsujimoto M 2002 The clinico- pathological signiﬁcance of histologic vascular invasion in differentiated thyroid carcinoma. Am J Surg 183:80–86. 559. Akslen LA, Myking AO, Salvesen H, Varhaug JE 1992 Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. Eur J Cancer 29A: 44–51. 560. Simpson WJ, McKinney SE, Carruthers JS, Gospodar- owicz MK, Sutcliffe
SB, Panzarella T 1987 Papillary and follicular thyroid cancer. Prognostic factors in 1,578 patients. Am J Med 83:479–488. 561. Mai KT, Khanna P, Yazdi HM, Perkins DG, Veinot JP, Thomas J, Lamba M, Nair BD 2002 Differentiated thy- roid carcinomas with vascular invasion: a comparative study of follicular, Hurthle cell and papillary thyroid carcinoma. Pathology 34:239–244.112 HAUGEN ET AL.
562. Furlan JC, Bedard YC, Rosen IB 2004 Clinicopathologic signiﬁcance of histologic vascular invasion in papillary and follicular thyroid carcinomas. J Am Coll Surg 198: 341–348. 563. Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M 2012 BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) 91:274–286. 564. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutationpredicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373–6379. 565. Elisei R, Viola D, Torregrossa L, Giannini R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, Valerio L, Materazzi G, Miccoli P, Piaggi P, Pinchera
A, Vitti P, Basolo F 2012 The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97:4390–4398. 566. Kim TY, Kim WB, Rhee YS, Song JY, Kim JM, Gong G, Lee S, Kim SY, Kim SC, Hong SJ, Shong YK 2006 The BRAF mutation is useful for prediction of clinical recur- rence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 65:364–368. 567. Li C, Lee KC, Schneider EB, Zeiger MA 2012 BRAFV600Emutation and its association with clinico- pathological features of papillary thyroid cancer: a meta- analysis. J Clin Endocrinol Metab 97:4559–4570. 568. Fernandez IJ, Piccin O, Sciascia S, Cavicchi O, Repaci A, Vicennati V, Fiorentino M 2013 Clinical signiﬁcance of BRAF mutation in thyroid papillary cancer. Otolar- yngol Head Neck Surg 148:919–925. 569. Prescott JD, Sadow
PM, Hodin RA, Le LP, Gaz RD, Randolph GW, Stephen AE, Parangi S, Daniels GH, Lubitz CC 2012 BRAFV600Estatus adds incremental va- lue to current risk classiﬁcation systems in predicting papillary thyroid carcinoma recurrence. Surgery 152: 984–990. 570. Sedliarou I, Saenko V, Lantsov D, Rogounovitch T, Namba H, Abrosimov A, Lushnikov E, Kumagai A, Nakashima M, Meirmanov S, Mine M, Hayashi T, Ya- mashita S 2004 The BRAFT1796A transversion is aprevalent mutational event in human thyroid micro- carcinoma. Int J Oncol 25:1729–1735. 571. Xing M 2007 BRAF mutation in papillary thyroid can- cer: pathogenic role, molecular bases, and clinical im- plications. Endocr Rev 28:742–762. 572. Park YJ, Kim YA, Lee YJ, Kim SH, Park SY, Kim KW, Chung JK, Youn YK, Kim KH, Park do J, Cho BY 2010 Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical ﬁndings. Head Neck 32:38–45. 573.
Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S 2003 Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393–4397. 574. Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR 2009 Association of BRAFV600E mutationwith poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 253:854–860. 575. Rodolico V, Cabibi D, Pizzolanti G, Richiusa P, Gebbia N, Martorana A, Russo A, Amato MC, Galluzzo A, Giordano C 2007 BRAF V600Emutation and p27 kip1 expression in papillary carcinomas of the thyroid <or= 1 cm and their paired lymph node metastases. Cancer 110:1218–1226. 576. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive ac- tivation of the RET/PTC-RAS-BRAF signaling pathwayin
papillary thyroid carcinoma. Cancer Res 63:1454– 1457. 577. Henderson YC, Shellenberger TD, Williams MD, El- Naggar AK, Fredrick MJ, Cieply KM, Clayman GL 2009 High rate of BRAF and RET/PTC dual mutations asso- ciated with recurrent papillary thyroid carcinoma. Clin Cancer Res 15:485–491. 578. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE 2013 Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab 98:E1852-E1860. 579. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK, Xing M 2013 Highly prevalent TERT promoter mutations in aggressive thyroid cancers. En- docr Relat Cancer 20:603–610. 580. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA 2013 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 98:E1562–E1566. 581. Liu X, Qu S,
Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M 2014 TERT promoter mutations and their as- sociation with BRAFV600Emutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 99:E1130–E1136. 582. Tuttle RM, Leboeuf R 2008 Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am 37:419–435, ix–x. 583. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez FF, Toft A, Wiersinga WM 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma:a European perspective. Eur J Endocrinol 150:105–112. 584. Tuttle RM 2008 Risk-adapted management of thyroid cancer. Endocr Pract 14:764–774. 585. Deleted. 586. Berger F, Friedrich U, Knesewitsch P, Hahn K 2011 Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer:
correlation of results to the individual risk proﬁle and long-term follow-up. Eur J Nucl Med Mol Imaging 38:451–458. 587. Malandrino P, Latina A, Marescalco S, Spadaro A, Re- galbuto C, Fulco RA, Scollo C, Vigneri R, Pellegriti G 2011 Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 96:1703– 1709. 588. Soyluk O, Boztepe H, Aral F, Alagol F, Ozbey NC 2011 Papillary thyroid carcinoma patients assessed to be atATA THYROID NODULE/DTC GUIDELINES 113
low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyro- globulin antibody positive or do not have distinctly low thyroglobulin at initial assessment. Thyroid 21:1301– 1308. 589. Piccardo A, Arecco F, Morbelli S, Bianchi P, Barbera F, Finessi M, Corvisieri S, Pestarino E, Foppiani L, Villa- vecchia G, Cabria M, Orlandi F 2010 Low thyroglobulin concentrations after thyroidectomy increase the prog- nostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differ- entiated thyroid cancer. J Endocrinol Invest 33:83–87. 590. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F 2008 Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH- stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. J Clin Endocrinol Metab 93:76–81. 591. Kloos RT, Mazzaferri EL 2005 A single
recombinant human thyrotropin-stimulated serum thyroglobulin mea- surement predicts differentiated thyroid carcinoma me- tastases three to ﬁve years later. J Clin Endocrinol Metab 90:5047–5057. 592. Kloos RT 2010 Thyroid cancer recurrence in patients clinically free of disease with undetectable or very low serum thyroglobulin values. J Clin Endocrinol Metab 95:5241–5248. 593. Han JM, Kim WB, Yim JH, Kim WG, Kim TY, Ryu JS, Gong G, Sung TY, Yoon JH, Hong SJ, Kim EY, Shong YK 2012 Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid 22:784–790. 594. Rosario PW, Furtado MS, Mineiro Filho AF, Lacerda RX, Calsolari MR 2012 Value of repeat stimulated thy- roglobulin testing in patients with differentiated thyroid carcinoma considered to be free of disease in the ﬁrst year after ablation. Thyroid 22:482–486. 595. Brassard M, Borget I, Edet-Sanson A, Giraudet AL, Mundler O, Toubeau M, Bonichon F,
Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Toubert ME, Torlontano M, Benhamou E, Schlumberger M 2011 Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab 96:1352–1359. 596. Pelttari H, Valimaki MJ, Loyttyniemi E, Schalin-Jantti C 2010 Post-ablative serum thyroglobulin is an indepen- dent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. Eur J Endocrinol 163:757–763. 597. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Wartofsky L 2011 Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission? Clin Endocrinol (Oxf) 74:111– 117. 598. Crocetti U, Durante C, Attard M, Maniglia A, Tumino S, Bruno R, Bonﬁtto N, Dicembrino F, Varraso A, Mer- ingolo D, Filetti S, Trischitta V, Torlontano M 2008 Predictive value of recombinant human TSH stimulation and neck ultrasonography in differentiated thyroid cancer patients. Thyroid
18:1049–1053. 599. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D’Azzo G, Meringolo D, Ferretti E,Sacco R, Arturi F, Filetti S 2004 Follow-up of low risk patients with papillary thyroid cancer: role of neck ul- trasonography in detecting lymph node metastases. J Clin Endocrinol Metab 89:3402–3407. 600. Verburg FA, Stokkel MP, Duren C, Verkooijen RB, Mader U, van Isselt JW, Marlowe RJ, Smit JW, Reiners C, Luster M 2010 No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37:276–283. 601. Giovanella L, Mafﬁoli M, Ceriani L, De PD, Spriano G 2009 Unstimulated high sensitive thyroglobulin mea- surement predicts outcome of differentiated thyroid carcinoma. Clin Chem Lab Med 47:1001–1004. 602. Momesso DP, Tuttle RM 2014 Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 43:401–421. 603. Lemb J, Hufner M, Meller
B, Homayounfar K, Sahlmann C, Meller J 2013 How reliable is secondary risk strati- ﬁcation with stimulated thyroglobulin in patients with differentiated thyroid carcinoma? Results from a retro- spective study. Nuklearmedizin 52:88–96. 604. Nascimento C, Borget I, Al Ghuzlan A, Deandreis D, Chami L, Travagli JP, Hartl D, Lumbroso J, Chougnet C, Lacroix L, Baudin E, Schlumberger M, Leboulleux S 2011 Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer 18:R29–R40. 605. Webb RC, Howard RS, Stojadinovic A, Gaitonde DY, Wallace MK, Ahmed J, Burch HB 2012 The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta- analysis involving 3947 patients. J Clin Endocrinol Metab 97:2754–2763. 606. Chindris AM, Diehl NN, Crook JE, Fatourechi V, Small- ridge RC 2012 Undetectable sensitive serum thyroglobulin (<0.1 ng/mL) in 163
patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ul- trasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 97:2714–2723. 607. Vaisman F, Tala H, Grewal R, Tuttle RM 2011 In dif- ferentiated thyroid cancer, an incomplete structural re- sponse to therapy is associated with signiﬁcantly worse clinical outcomes than only an incomplete thyroglobulinresponse. Thyroid 21:1317–1322. 608. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, Rimmele H, Seregni E, Smit JW, Theimer C, Giovanella L 2013 Implications of thyroglobulin antibody positivity in patients with dif- ferentiated thyroid cancer: a clinical position statement. Thyroid 23:1211–1225. 609. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: prevalence, in- ﬂuence on serum thyroglobulin measurement, and prog- nostic signiﬁcance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 83:1121–1127.
610. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY 2002 Clinical signiﬁcance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. Clin Endocrinol (Oxf) 57:215–221.114 HAUGEN ET AL.
611. Gorges R, Maniecki M, Jentzen W, Sheu SN, Mann K, Bockisch A, Janssen OE 2005 Development and clinical impact of thyroglobulin antibodies in patients with dif- ferentiated thyroid carcinoma during the ﬁrst 3 years after thyroidectomy. Eur J Endocrinol 153:49–55. 612. Seo JH, Lee SW, Ahn BC, Lee J 2010 Recurrence de- tection in differentiated thyroid cancer patients with el- evated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf) 72:558–563. 613. Adil A, Jafri RA, Waqar A, Abbasi SA, Matiul H, As- ghar AH, Jilani A, Naz I 2003 Frequency and clinical importance of anti-Tg auto-antibodies (ATG). J CollPhysicians Surg Pak 13:504–506. 614. Kim WG, Yoon JH, Kim WB, Kim TY, Kim EY, Kim JM, Ryu JS, Gong G, Hong SJ, Shong YK 2008 Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin- negative patients with differentiated
thyroid carcinoma. J Clin Endocrinol Metab 93:4683–4689. 615. Chiovato L, Latrofa F, Braverman LE, Pacini F, Ca- pezzone M, Masserini L, Grasso L, Pinchera A 2003 Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 139:346–351. 616. Thomas D, Liakos V, Vassiliou E, Hatzimarkou F, Tsatsoulis A, Kaldrimides P 2007 Possible reasons for different pattern disappearance of thyroglobulin and thyroid peroxidase autoantibodies in patients with dif- ferentiated thyroid carcinoma following total thyroidec- tomy and iodine-131 ablation. J Endocrinol Invest 30: 173–180. 617. Castagna MG, Tala Jury HP, Cipri C, Belardini V, Fioravanti C, Pasqui L, Sestini F, Theodoropoulou A, Pacini F 2011 The use of ultrasensitive thyroglobulin assays reduces but does not abolish the need for TSH stimulation in patients with differentiated thyroid carci- noma. J Endocrinol Invest 34:e219-e223. 618. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Tra- vagli JP, Schlumberger M 2003
Positive predictive value of serum thyroglobulin levels, measured during the ﬁrst year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 88: 1107–1111. 619. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J 1995 Iodine-131 therapy for thyroid cancer patients with ele-vated thyroglobulin and negative diagnostic scan. J Clin Endocrinol Metab 80:1488–1492. 620. Alzahrani AS, Mohamed G, Al Shammary A, Aldasouqi S, Abdal Salam S, Shoukri M 2005 Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J Endocrinol Invest 28:540–546. 621. Valadao MM, Rosario PW, Borges MA, Costa GB, Re- zende LL, Padrao EL, Barroso AL, Purisch S 2006 Po- sitive predictive value of detectable stimulated tg during the ﬁrst year after therapy of thyroid cancer and the value of comparison with Tg-ablation and Tg measured after 24 months. Thyroid 16:1145–1149. 622.
Miyauchi A, Kudo T, Miya A, Kobayashi K, Ito Y, Takamura Y, Higashiyama T, Fukushima M, Kihara M, Inoue H, Tomoda C, Yabuta T, Masuoka H 2011 Prog- nostic impact of serum thyroglobulin doubling-time un-der thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid 21:707–716. 623. Wong H, Wong KP, Yau T, Tang V, Leung R, Chiu J, Lang BH 2012 Is there a role for unstimulated thyro- globulin velocity in predicting recurrence in papillary thyroid carcinoma patients with detectable thyroglobulin after radioiodine ablation? Ann Surg Oncol 19:3479–3485. 624. Padovani RP, Robenshtok E, Brokhin M, Tuttle RM 2012 Even without additional therapy, serum thyro- globulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in pa- tients with differentiated thyroid cancer. Thyroid 22: 778–783. 625. Hsieh CJ, Wang PW 2014 Sequential changes of serum antithyroglobulin antibody levels are a good predictor of disease
activity in thyroglobulin-negative patients withpapillary thyroid carcinoma. Thyroid 24:488–493. 626. Schuff KG, Weber SM, Givi B, Samuels MH, Andersen PE, Cohen JI 2008 Efﬁcacy of nodal dissection for treatment of persistent/recurrent papillary thyroid cancer. Laryngoscope 118:768–775. 627. Al-Saif O, Farrar WB, Bloomston M, Porter K, Ringel MD, Kloos RT 2010 Long-term efﬁcacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab 95:2187–2194. 628. Yim JH, Kim WB, Kim EY, Kim WG, Kim TY, Ryu JS, Gong G, Hong SJ, Shong YK 2011 The outcomes of ﬁrst reoperation for locoregionally recurrent/persistent papil- lary thyroid carcinoma in patients who initially under- went total thyroidectomy and remnant ablation. J Clin Endocrinol Metab 96:2049–2056. 629. Rondeau G, Fish S, Hann LE, Fagin JA, Tuttle RM 2011 Ultrasonographically detected small thyroid bed nodules identiﬁed after total thyroidectomy for differentiated thyroid cancer seldom show clinically signiﬁcant struc- tural progression. Thyroid 21:845–853. 630.
Giovanella L, Ceriani L, Suriano S, Ghelfo A, Mafﬁoli M 2008 Thyroglobulin measurement before rhTSH- aided 131I ablation in detecting metastases from differ- entiated thyroid carcinoma. Clin Endocrinol (Oxf) 69:659–663. 631. Giovanella L, Ceriani L, Ghelfo A, Keller F 2005 Thyroglobulin assay 4 weeks after thyroidectomy pre- dicts outcome in low-risk papillary thyroid carcinoma. Clin Chem Lab Med 43:843–847. 632. Phan HT, Jager PL, van der Wal JE, Sluiter WJ, Plukker JT, Dierckx RA, Wolffenbuttel BH, Links TP 2008 The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur J Endocrinol 158:77–83. 633. Vaisman A, Orlov S, Yip J, Hu C, Lim T, Dowar M, Freeman JL, Walﬁsh PG 2010 Application of post- surgical stimulated thyroglobulin for radioiodine rem- nant ablation selection in low-risk papillary thyroid carcinoma. Head Neck 32:689–698. 634. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim
SC, Hong SJ, Shong YK 2005 Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidec- tomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carci- noma. J Clin Endocrinol Metab 90:1440–1445. 635. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, Riedinger JM, Boichot C, Cochet A,ATA THYROID NODULE/DTC GUIDELINES 115
Brunotte F 2004 Predictive value for disease progression of serum thyroglobulin levels measured in the postop- erative period and after (131)I ablation therapy in pa- tients with differentiated thyroid cancer. J Nucl Med 45:988–994. 636. Piccardo A, Arecco F, Puntoni M, Foppiani L, Cabria M, Corvisieri S, Arlandini A, Altrinetti V, Bandelloni R, Orlandi F 2013 Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong pre- dictor of disease persistence and is associated to progression-free survival and overall survival. Clin Nucl Med 38:18–24. 637. Polachek A, Hirsch D, Tzvetov G, Grozinsky-Glasberg S, Slutski I, Singer J, Weinstein R, Shimon I, Benbassat CA 2011 Prognostic value of post-thyroidectomy thy- roglobulin levels in patients with differentiated thyroid cancer. J Endocrinol Invest 34:855–860. 638. Hall FT, Beasley NJ, Eski SJ, Witterick IJ, Walﬁsh PG, Freeman JL 2003 Predictive value of serum thyroglob- ulin after surgery for thyroid carcinoma. Laryngoscope
113:77–81. 639. Heemstra KA, Liu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, Romijn JA, Smit JW 2007 Serum thyro- globulin concentrations predict disease-free remission and death in differentiated thyroid carcinoma. Clin En- docrinol (Oxf) 66:58–64. 640. Ronga G, Filesi M, Ventroni G, Vestri AR, Signore A 1999 Value of the ﬁrst serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma. Eur J Nucl Med 26:1448–1452. 641. Lin JD, Huang MJ, Hsu BR, Chao TC, Hsueh C, Liu FH, Liou MJ, Weng HF 2002 Signiﬁcance of postopera- tive serum thyroglobulin levels in patients with papillary and follicular thyroid carcinomas. J Surg Oncol 80:45–51. 642. Ibrahimpasic T, Nixon IJ, Palmer FL, Whitcher MM, Tuttle RM, Shaha A, Patel SG, Shah JP, Ganly I 2012 Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer—is there a need for radioactive iodine
therapy? Surgery 152:1096–1105. 643. Avram AM, Fig LM, Frey KA, Gross MD, Wong KK 2013 Preablation 131-I scans with SPECT/CT in post- operative thyroid cancer patients: what is the impact on staging? J Clin Endocrinol Metab 98:1163–1171. 644. Nascimento C, Borget I, Troalen F, Al Ghuzlan A, Deandreis D, Hartl D, Lumbroso J, Chougnet CN, Bau- din E, Schlumberger M, Leboulleux S 2013 Ultra- sensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. Eur J Endocrinol 169:689–693. 645. Rosario PW, Xavier AC, Calsolari MR 2011 Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid 21:49–53. 646. Robenshtok E, Grewal RK, Fish S, Sabra M, Tuttle RM 2013 A low postoperative nonstimulated serum thyro- globulin level does not exclude the presence of radioactive iodine avid
metastatic foci in intermediate-risk differen- tiated thyroid cancer patients. Thyroid 23:436–442. 647. de Rosario PW, Guimaraes VC, Maia FF, Fagundes TA, Purisch S, Padrao EL, Rezende LL, Barroso AL 2005Thyroglobulin before ablation and correlation with posttreatment scanning. Laryngoscope 115:264–267. 648. Park EK, Chung JK, Lim IH, Park do J, Lee DS, Lee MC, Cho BY 2009 Recurrent/metastatic thyroid carci- nomas false negative for serum thyroglobulin but posi- tive by posttherapy I-131 whole body scans. Eur J Nucl Med Mol Imaging 36:172–179. 649. Giovanella L, Suriano S, Ceriani L, Verburg FA 2011 Undetectable thyroglobulin in patients with differenti- ated thyroid carcinoma and residual radioiodine uptake on a postablation whole-body scan. Clin Nucl Med 36:109–112. 650. Oyen WJ, Verhagen C, Saris E, van den Broek WJ, Pieters GF, Corsten FH 2000 Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal. J Nucl Med 41:643–646. 651. Tamilia M, Al-Kahtani
N, Rochon L, Hier MP, Payne RJ, Holcroft CA, Black MJ 2011 Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mCi iodine-131 treatment in patients with papillary thyroid carcinoma. Nucl Med Commun 32:212–220. 652. Bernier MO, Morel O, Rodien P, Muratet JP, Giraud P, Rohmer V, Jeanguillaume C, Bigorgne JC, Jallet P 2005 Prognostic value of an increase in the serum thyroglob- ulin level at the time of the ﬁrst ablative radioiodine treatment in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 32:1418–1421. 653. Feldt-Rasmussen U, Petersen PH, Date J, Madsen CM 1982 Serum thyroglobulin in patients undergoing sub- total thyroidectomy for toxic and nontoxic goiter. J En- docrinol Invest 5:161–164. 654. Feldt-Rasmussen U, Petersen PH, Nielsen H, Date J, Madsen CM 1978 Thyroglobulin of varying molecular sizes with different disappearance rates in plasma fol- lowing subtotal thyroidectomy. Clin Endocrinol (Oxf) 9:205–214. 655. Izumi M, Kubo
I, Taura M, Yamashita S, Morimoto I, Ohtakara S, Okamoto S, Kumagai LF, Nagataki S 1986 Kinetic study of immunoreactive human thyroglobulin. J Clin Endocrinol Metab 62:410–412. 656. Hocevar M, Auersperg M, Stanovnik L 1997 The dy- namics of serum thyroglobulin elimination from the body after thyroid surgery. Eur J Surg Oncol 23:208–210. 657. Gerfo PL, Colacchio T, Colacchio D, Feind C 1978 Serum clearance rates of immunologically reactive thy-roglobulin. Cancer 42:164–166. 658. Giovanella L, Ceriani L, Mafﬁoli M 2010 Postsurgery serum thyroglobulin disappearance kinetic in patients with differentiated thyroid carcinoma. Head Neck 32: 568–571. 659. Lee JI, Chung YJ, Cho BY, Chong S, Seok JW, Park SJ 2013 Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. Surgery 153:828–835. 660. Lepoutre-Lussey C, Maddah D, Golmard JL, Russ G, Tissier F, Tresallet C, Menegaux F,
Aurengo A, Leen- hardt L 2014 Post-operative neck ultrasound and risk stratiﬁcation in differentiated thyroid cancer patients with initial lymph node involvement. Eur J Endocrinol 170:837–846. 661. Chen MK, Yasrebi M, Samii J, Staib LH, Doddamane I, Cheng DW 2012 The utility of I-123 pretherapy scan in116 HAUGEN ET AL.
I-131 radioiodine therapy for thyroid cancer. Thyroid 22:304–309. 662. Van Nostrand D, Aiken M, Atkins F, Moreau S, Garcia C, Acio E, Burman K, Wartofsky L 2009 The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer. Thyroid 19:849– 855. 663. Hu YH, Wang PW, Wang ST, Lee CH, Chen HY, Chou FF, Huang YE, Huang HH 2004 Inﬂuence of 131I di- agnostic dose on subsequent ablation in patients with differentiated thyroid carcinoma: discrepancy between the presence of visually apparent stunning and the im- pairment of successful ablation. Nucl Med Commun25:793–797. 664. Morris LF, Waxman AD, Braunstein GD 2001 The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and nonscanned individuals. J Clin En- docrinol Metab 86:3507–3511. 665. Muratet JP, Daver A, Minier JF, Larra F 1998 Inﬂuence of scanning doses of iodine-131 on subsequent ﬁrst ablative treatment outcome in patients operated on
for differenti- ated thyroid carcinoma. J Nucl Med 39:1546–1550. 666. Silberstein EB 2007 Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radio- iodine ablation in differentiated thyroid carcinoma. J Nucl Med 48:1043–1046. 667. Leger FA, Izembart M, Dagousset F, Barritault L, Baillet G, Chevalier A, Clerc J 1998 Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine- 131 diagnostic imaging for thyroid remnants in differ- entiated thyroid carcinoma. Eur J Nucl Med 25:242–246. 668. Verkooijen RB, Verburg FA, van Isselt JW, Lips CJ, Smit JW, Stokkel MP 2008 The success rate of I-131 ablation in differentiated thyroid cancer: comparison of uptake-related and ﬁxed-dose strategies. Eur J En- docrinol 159:301–307. 669. Verburg FA, Verkooijen RB, Stokkel MP, van Isselt JW 2009 The success of 131I ablation in thyroid cancer patients is signiﬁcantly reduced after a diagnostic activ- ity of 40 MBq 131I. Nuklearmedizin 48:138–142. 670. Yap BK, Murby
B 2014 No adverse affect in clinical outcome using low preablation diagnostic (131)I activity in differentiated thyroid cancer: refuting thyroid- stunning effect. J Clin Endocrinol Metab 99:2433–2440. 671. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW,Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differenti- ated thyroid carcinoma following initial therapy. Thyroid 16:1229–1242. 672. Jonklaas J, Cooper DS, Ain KB, Bigos T, Brierley JD, Haugen BR, Ladenson PW, Magner J, Ross DS, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2010 Radioiodine therapy in patients with stage I differenti- ated thyroid cancer. Thyroid 20:1423–1424. 673. Sacks W, Fung CH, Chang JT, Waxman A, Braunstein GD 2010 The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic anal- ysis of the peer-reviewed literature from 1966 to April 2008. Thyroid 20:1235–1245.
674. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rot- stein L, Gafni A, Straus S, Goldstein DP 2008 An up- dated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation inwell-differentiated thyroid cancer. Endocrinol Metab Clin North Am 37:457–480. 675. Lamartina L, Durante C, Filetti S, Cooper DS 2015 Low- risk differentiated thyroid cancer and radioiodine rem- nant ablation: a systematic review of the literature. J Clin Endocrinol Metab 100:1748–1761. 676. Ross DS, Litofsky D, Ain KB, Bigos T, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2009 Recurrence after treatment of micropapillary thyroid cancer. Thyroid 19: 1043–1048. 677. Kim HJ, Kim NK, Choi JH, Kim SW, Jin SM, Suh S, Bae JC, Min YK, Chung JH, Kim SW 2013 Radioactiveiodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Clin Endocrinol (Oxf) 78:614–620. 678. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno- Bossio G, Caillou B, Cailleux AF, Lumbroso JD, Par- mentier C, Schlumberger M 1998 Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 83:553–559. 679. Creach KM, Siegel BA, Nussenbaum B, Grigsby PW 2012 Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcino ma. ISRN Endocrinol 2012: 816386. 680. Lin HW, Bhattacharyya N 2009 Survival impact of treatment options for papillary microcarcinoma of the thyroid. Laryngoscope 119:1983–1987. 681. Kuo EJ, Roman SA, Sosa JA 2013 Patients with follic- ular and Hurthle cell microcarcinomas have compro- mised survival: a population level study of 22,738 patients. Surgery 154:1246–1253. 682. Mallick U, Harmer C, Hackshaw A, Moss L 2012 Iodine or Not (IoN) for low-risk differen tiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol (R Coll Radiol ) 24:159–161. 683.
Kazaure HS, Roman SA, Sosa JA 2012 Aggressive variants of papillary thyroid cancer: incidence, charac- teristics and predictors of survival among 43,738 pa- tients. Ann Surg Oncol 19:1874–1880. 684. Kazaure HS, Roman SA, Sosa JA 2012 Insular thyroid cancer: a population-level analysis of patient character- istics and predictors of survival. Cancer 118:3260–3267. 685. Ruel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA 2015 Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer. J Clin En-docrinol Metab 100:1529–1536. 686. Chow SM, Yau S, Kwan CK, Poon PC, Law SC 2006 Local and regional control in patients with papillary thy- roid carcinoma: speciﬁc indications of external radiother- apy and radioactive iodine according to T and N categories in AJCC 6th edition. Endocr Relat Cancer 13:1159–1172. 687. Podnos YD, Smith DD, Wagman LD, Ellenhorn JD 2007 Survival in patients with papillary thyroid cancer
is not affected by the use of radioactive isotope. J Surg Oncol 96:3–7. 688. Chakravarty D, Santos E, Ryder M, Knauf JA, Liao XH, West BL, Bollag G, Kolesnick R, Thin TH, Rosen N, Zanzonico P, Larson SM, Refetoff S, Ghossein R, Fagin JA 2011 Small-molecule MAPK inhibitors restore radio- iodine incorporation in mouse thyroid cancers with con- ditional BRAF activation. J Clin Invest 121:4700–4711. 689. Edmonds CJ, Hayes S, Kermode JC, Thompson BD 1977 Measurement of serum TSH and thyroid hormones in theATA THYROID NODULE/DTC GUIDELINES 117
management of treatment of thyroid carcinoma with radioiodine. Br J Radiol 50:799–807. 690. Leboeuf R, Perron P, Carpentier AC, Verreault J, Lan- glois MF 2007 L-T3 preparation for whole-body scin- tigraphy: a randomized-controlled trial. Clin Endocrinol (Oxf) 67:839–844. 691. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS 2010 Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differenti- ated thyroid carcinoma. Thyroid 20:173–179. 692. Fallahi B, Beiki D, Takavar A, Fard-Esfahani A, Gilani KA, Saghari M, Eftekhari M 2012 Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial. Nucl Med Commun 33:275–282. 693. Goropoulos A, Karamoshos K, Christodoulou A, Ntitsias T, Paulou K, Samaras A, Xirou P, Efstratiou I 2004 Value of the cervical compartments in the surgical treatment
of papillary thyroid carcinoma. World J Surg 28:1275–1281. 694. Molinaro E, Giani C, Agate L, Biagini A, Pieruzzi L, Bianchi F, Brozzi F, Ceccarelli C, Viola D, Piaggi P, Vitti P, Pacini F, Elisei R 2013 Patients with differenti- ated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity131I after either re- combinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up. J Clin Endocrinol Metab 98:2693–2700. 695. Prpic M, Dabelic N, Stanicic J, Jukic T, Milosevic M, Kusic Z 2012 Adjuvant thyroid remnant ablation in pa- tients with differentiated thyroid carcinoma conﬁned to the thyroid: a comparison of ablation success with dif- ferent activities of radioiodine (I-131). Ann Nucl Med 26:744–751. 696. Karam M, Gianoukakis A, Feustel PJ, Cheema A, Postal ES, Cooper JA 2003 Inﬂuence of diagnostic and thera- peutic doses on thyroid remnant ablation rates. Nucl Med Commun 24:489–495. 697.
Robbins RJ, Driedger A, Magner J 2006 Recombinant human thyrotropin-assisted radioiodine therapy for pa- tients with metastatic thyroid cancer who could not ele- vate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16:1121–1130. 698. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E 2009 Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 160:431–436. 699. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A 2012 Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med
366:1674–1685. 700. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Del-passand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an interna- tional, randomized, controlled study. J Clin Endocrinol Metab 91:926–932. 701. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz C, Vera P, Morel O, Benisvy D, Bournaud C, Bonichon F, Dejax C, Toubert ME, Leboulleux S, Ricard M, Benhamou E 2012 Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 366:1663–1673. 702. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, de Micco C,
Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O 2009 Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 71:115–123. 703. Emmanouilidis N, Muller JA, Jager MD, Kaaden S, Helfritz FA, Guner Z, Kespohl H, Knitsch W, Knapp WH, Klempnauer J, Scheumann GF 2009 Surgery and radioablation therapy combined: introducing a 1-week- condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH. Eur J Endocrinol 161:763–769. 704. Tu J, Wang S, Huo Z, Lin Y, Li X, Wang S 2014 Re- combinant human thyrotropin-aided versus thyroid hor- mone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis. Radiother Oncol 110:25–30. 705. Pak K, Cheon GJ, Kang KW, Kim SJ, Kim IJ, Kim EE, Lee DS, Chung JK 2014 The effectiveness of
recombi- nant human thyroid-stimulating hormone versus thyroid hormone withdrawal prior to radioiodine remnant abla- tion in thyroid cancer: a meta-analysis of randomized controlled trials. J Korean Med Sci 29:811–817. 706. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lass- mann M, Busaidy NL, Wahl RL, Pacini F, Cho SY,Magner J, Pinchera A, Ladenson PW 2009 Follow-up of low-risk differentiated thyroid cancer patients who un- derwent radioiodine ablation of postsurgical thyroidremnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94:4171–4179. 707. Emmanouilidis N, Schrem H, Winkler M, Klempnauer J, Scheumann GF 2013 Long-term results after treatment of very low-, low-, and high-risk thyroid cancers in a combined setting of thyroidectomy and radio ablation therapy in euthyroidism. Int J Endocrinol 2013: 769473. 708. Hugo J, Robenshtok E, Grewal R,
Larson S, Tuttle RM 2012 Recombinant human thyroid stimulating hormone- assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid 22:1007–1015. 709. Rosario PW, Mineiro Filho AF, Lacerda RX, Calsolari MR 2012 Long-term follow-up of at least ﬁve years after recombinant human thyrotropin compared to levothyr- oxine withdrawal for thyroid remnant ablation with ra- dioactive iodine. Thyroid 22:332–333.118 HAUGEN ET AL.
710. Pitoia F, Marlowe RJ, Abelleira E, Faure EN, Bueno F, Schwarzstein D, Lutﬁ RJ, Niepomniszcze H 2012 Radioiodine thyroid remnant ablation after recombinant human thyrotropin or thyroid hormone withdrawal in patients with high-risk differentiated thyroid cancer. J Thyroid Res 2012: 481568. 711. Bartenstein P, Calabuig EC, Maini CL, Mazzarotto R, Muros de Fuentes MA, Petrich T, Rodrigues FJ, Vallejo Casas JA, Vianello F, Basso M, Balaguer MG, Haug A, Monari F, Vano RS, Sciuto R, Magner J 2014 High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. Thyroid 24:480– 487. 712. Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM 2011 Five-year survival is similar in thyroid cancer pa- tients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab 96:2105–2111. 713. Klubo-Gwiezdzinska J, Burman KD,
Van Nostrand D, Mete M, Jonklaas J, Wartofsky L 2012 Radioiodine treatment of metastatic thyroid cancer: relative efﬁcacy and side effect proﬁle of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid 22:310–317. 714. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H 2008 Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. PLoS One 3:e1885. 715. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine admin- istered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542–3546. 716. Zaman M, Toor R, Kamal S, Maqbool M, Habib S, Niaz K 2006 A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation
of differentiated thyroid cancers. J Pak Med Assoc 56:353–356. 717. Kukulska A, Krajewska J, Gawkowska-Suwinska M, Puch Z, Paliczka-Cieslik E, Roskosz J, Handkiewicz- Junak D, Jarzab M, Gubala E, Jarzab B 2010 Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison oflong-term outcomes of treatment with 30, 60 and 100 mCi. Thyroid Res 3:9. 718. Fang Y, Ding Y, Guo Q, Xing J, Long Y, Zong Z 2013 Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses. J Endocrinol Invest 36:896– 902. 719. Ma C, Tang L, Fu H, Li J, Wang H 2013 rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis. Nucl Med Commun 34:1150–1156. 720. Cheng W, Ma C, Fu H, Li J, Chen S, Wu S, Wang H 2013 Low- or high-dose radioiodine remnant ablation for differentiated thyroid carcinoma:
a meta-analysis. J Clin Endocrinol Metab 98:1353–1360. 721. Valachis A, Nearchou A 2013 High versus low radio- iodine activity in patients with differentiated thyroid cancer: a meta-analysis. Acta Oncol 52:1055–1061.722. Verburg FA, Mader U, Reiners C, Hanscheid H 2014 Long term survival in DTC is worse after low-activity initial post-surgical I-131 therapy in both high and low risk patients. J Clin Endocrinol Metab 99:4487–4496. 723. Castagna MG, Cevenini G, Theodoropoulou A, Maino F, Memmo S, Claudia C, Belardini V, Brianzoni E, Pacini F 2013 Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in in- termediate risk differentiated thyroid cancer patients. Eur J Endocrinol 169:23–29. 724. Han JM, Kim WG, Kim TY, Jeon MJ, Ryu JS, Song DE, Hong SJ, Shong YK, Kim WB 2014 Effects of low-doseand high-dose postoperative radioiodine therapy on theclinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal exten-
sion. Thyroid 24:820–825. 725. Kruijff S, Aniss AM, Chen P, Sidhu SB, Delbridge LW, Robinson B, Clifton-Bligh RJ, Roach P, Gill AJ, Learoyd D, Sywak MS 2013 Decreasing the dose of radioiodine for remnant ablation does not increase structural recur- rence rates in papillary thyroid carcinoma. Surgery 154: 1337–1344. 726. Sabra M, Grewal R, Ghossein RM, Tuttle RM 2014 Higher administered activities of radi oactive iodine are associated with less structural persistent response in older, but not younger, papillary thyroid cancer patients with lateral neck lymph node metastases. Thyroid 24:1088–1095. 727. Sawka AM, Ibrahim-Zada I, Galacgac P, Tsang RW, Brierley JD, Ezzat S, Goldstein DP 2010 Dietary iodine restriction in preparation for radioactive iodine treatment or scanning in well-differentiated thyroid cancer: a sys- tematic review. Thyroid 20:1129–1138. 728. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, Romijn JA, Smit JW 2003 Effects of low-iodide diet on
postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 58:428–435. 729. Morris LF, Wilder MS, Waxman AD, Braunstein GD 2001 Reevaluation of the impact of a stringent low- iodine diet on ablation rates in radioiodine treatment of thyroid carcinoma. Thyroid 11:749–755. 730. Morsch EP, Vanacor R, Furlanetto TW, Schmid H 2011 Two weeks of a low-iodine diet are equivalent to 3 weeks for lowering urinary iodine and increasing thyroid radioactive iodine uptake. Thyroid 21:61–67. 731. Tala Jury HP, Castagna MG, Fioravanti C, Cipri C, Brianzoni E, Pacini F 2010 Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 95:230–237. 732. Al Nozha OM, Vautour L, How J 2011 Life-threatening hyponatremia following a low-iodine diet: a case report and review of all reported cases. Endocr Pract 17:e113-e117. 733. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr,
La- denson PW 1994 Clinical utility of posttreatment radio- iodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 78:629–634. 734. Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechi GZ, Thorson LM, Gorman CA 2000 Are posttherapy radioiodine scans informative and do they inﬂuence subsequent therapy of patients with dif- ferentiated thyroid cancer? Thyroid 10:573–577. 735. Souza Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Penna GC, Purisch S 2004 Post I-131ATA THYROID NODULE/DTC GUIDELINES 119
therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribu- tion? Clin Nucl Med 29:795–798. 736. Spies WG, Wojtowicz CH, Spies SM, Shah AY, Zimmer AM 1989 Value of post-therapy whole-body I-131 im- aging in the evaluation of patients with thyroid carci- noma having undergone high-dose I-131 therapy. Clin Nucl Med 14:793–800. 737. Ciappuccini R, Heutte N, Trzepla G, Rame JP, Vaur D, Aide N, Bardet S 2011 Postablation (131)I scintigraphy with neck and thorax SPECT-CT and stimulated serum thyroglobulin level predict the outcome of patients with differentiated thyroid cancer. Eur J Endocrinol 164:961– 969. 738. Salvatori M, Perotti G, Villani MF, Mazza R, Maussier ML, Indovina L, Sigismondi A, Dottorini ME, Giordano A 2013 Determining the appropriate time of execution of an I-131 post-therapy whole-body scan: comparison between early and late imaging. Nucl Med Commun 34:900–908. 739. Kohlfuerst S, Igerc I, Lobnig M, Gallowitsch
HJ, Gomez-Segovia I, Matschnig S, Mayr J, Mikosch P, Beheshti M, Lind P 2009 Posttherapeutic (131)I SPECT- CT offers high diagnostic accuracy when the ﬁndings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen. Eur J Nucl Med Mol Imaging 36:886–893. 740. Chen L, Luo Q, Shen Y, Yu Y, Yuan Z, Lu H, Zhu R 2008 Incremental value of 131I SPECT/CT in the man- agement of patients with differentiated thyroid carci- noma. J Nucl Med 49:1952–1957. 741. Schmidt D, Linke R, Uder M, Kuwert T 2010 Five months’ follow-up of patients with and without iodine- positive lymph node metastases of thyroid carcinoma as disclosed by (131)I-SPECT/CT at the ﬁrst radioablation. Eur J Nucl Med Mol Imaging 37:699–705. 742. Maruoka Y, Abe K, Baba S, Isoda T, Sawamoto H, Tanabe Y, Sasaki M, Honda H 2012 Incremental diag- nostic value of SPECT/CT with 131I scintigraphy after
radioiodine therapy in patients with well-differentiated thyroid carcinoma. Radiology 265:902–909. 743. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, Strauss HW, Larson SM, Schoder H 2010 The effect of posttherapy 131I SPECT/CT on risk classiﬁcation and management of patients with differentiated thyroid can- cer. J Nucl Med 51:1361–1367. 744. Brabant G 2008 Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin En- docrinol Metab 93:1167–1169. 745. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ 2002 Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554–564. 746. Diessl S, Holzberger B, Mader U, Grelle I, Smit JW, Buck AK, Reiners C, Verburg FA 2012 Impact of moderate vs stringent TSH suppression on survival in advanced differentiated thyroid carcinoma. Clin En- docrinol (Oxf) 76:586–592. 747. Biondi B, Cooper DS 2010 Beneﬁts of thyrotropin sup- pression
versus the risks of adverse effects in differen- tiated thyroid cancer. Thyroid 20:135–146. 748. Sugitani I, Fujimoto Y 2011 Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospec- tive controlled study. Surgery 150:1250–1257.749. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jafﬁol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318–4323. 750. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW 2007 Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab92:2610–2615. 751. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D’Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial ﬁbrillation in older persons. N Engl JMed 331:1249–1252. 752. Toft AD 2001 Clinical practice. Subclinical
hyperthy- roidism. N Engl J Med 345:512–516. 753. Chen CH, Chen JF, Yang BY, Liu RT, Tung SC, Chien WY, Lu YC, Kuo MC, Hsieh CJ, Wang PW 2004 Bone mineral density in women receiving thyroxine suppres- sive therapy for differentiated thyroid carcinoma. J Formos Med Assoc 103:442–447. 754. Panico A, Lupoli GA, Fonderico F, Marciello F, Marti- nelli A, Assante R, Lupoli G 2009 Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate. Thyroid 19:437–442. 755. Ebina A, Sugitani I, Fujimoto Y, Yamada K 2014 Risk- adapted management of papillary thyroid carcinoma according to our own risk group classiﬁcation system: is thyroid lobectomy the treatment of choice for low-risk patients? Surgery 156:1579–1588. 756. Ford D, Giridharan S, McConkey C, Hartley A, Bram- mer C, Watkinson JC, Glaholm J 2003 External beam radiotherapy in the management of differentiated thyroid cancer. Clin Oncol (R Coll Radiol ) 15:337–341. 757. Terezakis SA, Lee
KS, Ghossein RA, Rivera M, Tuttle RM, Wolden SL, Zelefsky MJ, Wong RJ, Patel SG, Pﬁster DG, Shaha AR, Lee NY 2009 Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience. Int J Radiat Oncol Biol Phys 73:795–801. 758. Brierley J, Tsang R, Panzarella T, Bana N 2005 Prog- nostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with dif- ferentiated thyroid cancer seen at a single institution over 40 years. Clin Endocrinol (Oxf) 63:418–427. 759. Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW 2007 An evidence-based review of poorly differ- entiated thyroid cancer. World J Surg 31:934–945. 760. Kim JH, Leeper RD 1987 Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 60:2372–2375. 761. Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA,
Boezen HM, Dullaart RP, de Vries EG, Sluiter WJ 2005 Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr Relat Cancer 12: 273–280. 762. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD 2008 The risk of second primary ma- lignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 93:504–515. 763. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C,120 HAUGEN ET AL.
Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. Br J Cancer 89:1638–1644. 764. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Salle F, Ma- houdeau J, Bardet S 2004 Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31:685–691. 765. Kim S, Wei JP, Braveman JM, Brams DM 2004 Pre- dicting outcome and directing therapy for papillary thy- roid carcinoma. Arch Surg 139:390–394. 766. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I 2011 Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactiveiodine therapy. Cancer 117:4439–4446. 767. Biondi B, Filetti S, Schlumberger M 2005 Thyroid- hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 1:32–40. 768. Diaz-Soto G, Puig-Domingo M, Martinez-Pino I, Mar- tinez de Osaba MJ, Mora M, Rivera-Fillat F, Halperin I 2011
Do thyroid cancer patients with basal undetectable Tg measured by current immunoassays require rhTSH testing? Exp Clin Endocrinol Diabetes 119:348–352. 769. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, Fatourechi V 2007 Monitoring thyroglob- ulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 92:82–87. 770. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielny S, Taieb D, Toubeau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet S, Bussiere F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, Ricard M, Benhamou E 2007 Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer pa- tients. J Clin Endocrinol Metab 92:2487–2495. 771. Spencer CA 2011 Clinical review:
Clinical utility of thyroglobulin antibody (TgAb) measurements for pa- tients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 96:3615–3627. 772. Taylor KP, Parkington D, Bradbury S, Simpson HL, Jefferies SJ, Halsall DJ 2011 Concordance between thyroglobulin antibody assays. Ann Clin Biochem 48: 367–369. 773. Giovanella L, Keller F, Ceriani L, Tozzoli R 2009 Het- erophile antibodies may falsely increase or decrease thy- roglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med 47:952–954. 774. Verburg FA, Waschle K, Reiners C, Giovanella L, Lentjes EG 2010 Heterophile antibodies rarely inﬂuence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Horm Metab Res 42:736–739. 775. Latrofa F, Ricci D, Montanelli L, Rocchi R, Piaggi P, Sisti E, Grasso L, Basolo F, Ugolini C, Pinchera A, Vitti P 2012 Lymphocytic thyroiditis on histology correlates with serum thyroglobulin autoantibodies in patients with papillary thyroid carcinoma: impact on detection
of se- rum thyroglobulin. J Clin Endocrinol Metab 97:2380– 2387. 776. Giovanella L, Ceriani L 2011 Comparison of thyro- globulin antibody interference in ﬁrst- and second-generation thyroglobulin immunoassays. Clin Chem Lab Med 49:1025–1027. 777. Stanojevic M, Savin S, Cvejic D, Djukic A, Jeremic M, Zivancevic SS 2009 Comparison of the inﬂuence of thyroglobulin antibodies on serum thyroglobulin values from two different immunoassays in post surgical dif- ferentiated thyroid carcinoma patients. J Clin Lab Anal 23:341–346. 778. Stanojevic M, Savin S, Cvejic D, Dukic A, Zivancevic SS 2009 Correlation of thyroglobulin concentrations measured by radioimmunoassay and immunoradiometricassay and the inﬂuence of thyroglobulin antibody. J Immunoassay Immunochem 30:197–207. 779. Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij- Corssmit EP, Pereira AM, Stokkel MP, Kievit J 2004 Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 61: 61–74. 780. Bachelot A, Leboulleux
S, Baudin E, Hartl DM, Caillou B, Travagli JP, Schlumberger M 2005 Neck recurrence from thyroid carcinoma: serum thyroglobulin and high- dose total body scan are not reliable criteria for cure after radioiodine treatment. Clin Endocrinol (Oxf) 62:376– 379. 781. Cherk MH, Francis P, Topliss DJ, Bailey M, Kalff V 2012 Incidence and implications of negative serum thy- roglobulin but positive I-131 whole-body scans in pa- tients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal. Clin En- docrinol (Oxf) 76:734–740. 782. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A 2001 Outcome of dif- ferentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus un- treated patients. J Clin Endocrinol Metab 86:4092–4097. 783. Torlontano M, Crocetti U, Augello G, D’Aloiso L, Bonﬁtto N, Varraso A, Dicembrino F,
Modoni S, Frus- ciante V, Di GA, Bruno R, Filetti S, Trischitta V 2006 Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole- body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid micro- carcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 91:60–63. 784. Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, Fleisher M, Tuttle RM 2004 Factors inﬂuencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab 89:6010–6016. 785. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433–1441. 786. Deleted. 787. Iervasi A, Iervasi
G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, Colato C, Zucchelli GC 2007 Clinical rele- vance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. Clin Endocrinol (Oxf) 67:434–441.ATA THYROID NODULE/DTC GUIDELINES 121
788. Spencer C, Fatemi S, Singer P, Nicoloff J, Lopresti J 2010 Serum basal thyroglobulin measured by a second- generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 20: 587–595. 789. Haugen BR, Pacini F, Reiners C, Schlumberger M, La- denson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Sam- uels MH, Becker DV, Maxon HR III, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropinand thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84: 3877–3885. 790. David A, Blotta A, Bondanelli M, Rossi R, Roti E, Braverman LE, Busutti L, degli Uberti EC 2001 Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration
of recombinant human thyroid- stimulating hormone. J Nucl Med 42:1470–1475. 791. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 87:1490–1498. 792. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT 2002 Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with re- combinant human thyrotropin. Thyroid 12:37–43. 793. Lima N, Cavaliere H, Tomimori E, Knobel M, Medeiros- Neto G 2002 Prognostic value of serial serum thyro- globulin determinations after total thyroidectomy for differentiated thyroid cancer. J Endocrinol Invest 25: 110–115. 794. Wartofsky L 2002 Management of low-risk well- differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid 12:583–590. 795. Schaap J, Eustatia-Rutten CF, Stokkel M, Links TP, Diamant M, van der Velde EA, Romijn JA, Smit JW 2002 Does radioiodine therapy have disadvantageous effects in
non-iodine accumulating differentiated thyroid carcinoma? Clin Endocrinol (Oxf) 57:117–124. 796. Pacini F, Sabra MM, Tuttle RM 2011 Clinical relevance of thyroglobulin doubling time in the management ofpatients with differentiated thyroid cancer. Thyroid 21: 691–692. 797. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT 1999 Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. Thy- roid9:435–441. 798. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499. 799. Spencer CA 2004 Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 89:3702–3704. 800. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli JP, Schlumberger M 2002 Relationship between tumor burden and serum thyro-globulin level
in patients with papillary and follicular thyroid carcinoma. Thyroid 12:707–711. 801. Spencer C, Fatemi S 2013 Thyroglobulin antibody (TgAb) methods—strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 27:701–712. 802. Nygaard B, Bentzen J, Laurberg P, Pedersen SM, Bas- tholt L, Handberg A, Rytter C, Godballe C, Faber J 2012 Large discrepancy in the results of sensitive measure- ments of thyroglobulin antibodies in the follow-up on thyroid cancer: a diagnostic dilemma. Eur Thyroid J 1: 193–197. 803. Hoofnagle AN, Becker JO, Wener MH, Heinecke JW 2008 Quantiﬁcation of thyroglobulin, a low-abundance serum protein, by immunoafﬁnity peptide enrichmentand tandem mass spectrometry. Clin Chem 54:1796– 1804. 804. Clarke NJ, Zhang Y, Reitz RE 2012 A novel mass spectrometry-based assay for the accurate measurement of thyroglobulin from patient samples containing an- tithyroglobulin autoantibodies. J Investig Med 60:1157– 1163. 805. Kushnir MM, Rockwood AL,
Roberts WL, Abraham D, Hoofnagle AN, Meikle AW 2013 Measurement of thyroglobulin by liquid chromatography-tandem mass spectrometry in serum and plasma in the presence of an- tithyroglobulin autoantibodies. Clin Chem 59:982–990. 806. Hoofnagle AN, Roth MY 2013 Clinical review: im- proving the measurement of serum thyroglobulin with mass spectrometry. J Clin Endocrinol Metab 98:1343– 1352. 807. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thy- roid carcinoma. J Clin Endocrinol Metab 88:3668–3673. 808. Shin JH, Han BK, Ko EY, Kang SS 2007 Sonographic ﬁndings in the surgical bed after thyroidectomy: com- parison of recurrent tumors and nonrecurrent lesions. J Ultrasound Med 26:1359–1366. 809. Bardet S, Malville E, Rame JP, Babin E, Samama G, De RD, Michels JJ, Reznik Y, Henry-Amar M
2008 Mac- roscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid car-cinoma. Eur J Endocrinol 158:551–560. 810. Torres MR, Nobrega Neto SH, Rosas RJ, Martins AL, Ramos AL, da Cruz TR 2014 Thyroglobulin in the washout ﬂuid of lymph-node biopsy: what is its role in the follow-up of differentiated thyroid carcinoma? Thy- roid24:7–18. 811. Frasoldati A, Toschi E, Zini M, Flora M, Caroggio A, Dotti C, Valcavi R 1999 Role of thyroglobulin mea- surement in ﬁne-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid can- cer. Thyroid 9:105–111. 812. Baloch ZW, Barroeta JE, Walsh J, Gupta PK, LiVolsi VA, Langer JE, Mandel SJ 2008 Utility of thyroglobulin measurement in ﬁne-needle aspiration biopsy specimens of lymph nodes in the diagnosis of recurrent thyroid carcinoma. Cytojournal 5:1–8. 813. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan122 HAUGEN
ET AL.
may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 87:1499–1501. 814. Torlontano M, Crocetti U, D’Aloiso L, Bonﬁtto N, Di GA, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V 2003 Serum thyroglobulin and 131I whole body scan after recombi- nant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J En- docrinol 148:19–24. 815. Aide N, Heutte N, Rame JP, Rousseau E, Loiseau C, Henry-Amar M, Bardet S 2009 Clinical relevance of single-photon emission computed tomography/computedtomography of the neck and thorax in postablation (131)I scintigraphy for thyroid cancer. J Clin Endocrinol Metab 94:2075–2084. 816. Schmidt D, Szikszai A, Linke R, Bautz W, Kuwert T 2009 Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the ﬁrst radio- ablation. J Nucl Med 50:18–23. 817.
Jeong SY, Lee SW, Kim HW, Song BI, Ahn BC, Lee J 2014 Clinical applications of SPECT/CT after ﬁrst I-131 ablation in patients with differentiated thyroid cancer. Clin Endocrinol (Oxf) 81:445–451. 818. Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, Sandler MP, Delbeke D 2004 Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carci- noma. Eur J Nucl Med Mol Imaging 31:1435–1442. 819. Freudenberg LS, Jentzen W, Stahl A, Bockisch A, Rosenbaum-Krumme SJ 2011 Clinical applications of 124I-PET/CT in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 38(Suppl 1): S48– S56. 820. Van Nostrand D, Moreau S, Bandaru VV, Atkins F, Chennupati S, Mete M, Burman K, Wartofsky L 2010 (124)I positron emission tomography versus (131)I planar imaging in the identiﬁcation of residual thyroid tissue and/or metastasis in patients who have well- differentiated thyroid cancer.
Thyroid 20:879–883. 821. Phan HT, Jager PL, Paans AM, Plukker JT, Sturkenboom MG, Sluiter WJ, Wolffenbuttel BH, Dierckx RA, Links TP 2008 The diagnostic value of 124I-PET in patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:958–965. 822. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW 2007 The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract Endocrinol Metab 3:112–121. 823. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]ﬂuoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 91:498–505. 824. Deandreis D, Al Ghuzlan A, Leboulleux S, Lacroix L, Garsi JP, Talbot M, Lumbroso J, Baudin E, Caillou B, Bidart JM, Schlumberger M 2011 Do histological, im- munohistochemical, and metabolic (radioiodine and ﬂuorodeoxyglucose uptakes) patterns of metastatic thy- roid cancer correlate with
patient outcome? Endocr Relat Cancer 18:159–169. 825. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, WahlRL, Sherman SI, Ladenson PW, Schlumberger M 2009 Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-ﬂuoro-2-deoxy- D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 94:1310– 1316. 826. Yoon DY, Hwang HS, Chang SK, Rho YS, Ahn HY, Kim JH, Lee IJ 2009 CT, MR, US,18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol 19:634–642. 827. Takashima S, Sone S, Takayama F, Wang Q, Kobayashi T, Horii A, Yoshida JI 1998 Papillary thyroid carcinoma: MR diagnosis of lymph node metastasis. AJNR Am J Neuroradiol 19:509–513. 828. Gross ND, Weissman JL, Talbot JM, Andersen PE, Wax MK, Cohen JI 2001 MRI detection
of cervical metastasis from differentiated thyroid carcinoma. Laryngoscope 111:1905–1909. 829. Toubert ME, Cyna-Gorse F, Zagdanski AM, Noel- Wekstein S, Cattan P, Billotey C, Sarfati E, Rain JD 1999 Cervicomediastinal magnetic resonance imaging in persistent or recurrent papillary thyroid carcinoma: clinical use and limits. Thyroid 9:591–597. 830. Wang JC, Takashima S, Takayama F, Kawakami S, Saito A, Matsushita T, Matsuba H, Kobayashi S 2001 Tracheal invasion by thyroid carcinoma: prediction using MR imaging. AJR Am J Roentgenol 177:929–936. 831. Wang J, Takashima S, Matsushita T, Takayama F, Ko- bayashi T, Kadoya M 2003 Esophageal invasion by thyroid carcinomas: prediction using magnetic resonance imaging. J Comput Assist Tomogr 27:18–25. 832. Lee DH, Kang WJ, Seo HS, Kim E, Kim JH, Son KR, Na DG 2009 Detection of metastatic cervical lymph nodes in recurrent papillary thyroid carcinoma: computed to- mography versus positron emission tomography-computed tomography. J Comput Assist Tomogr 33:805–810. 833. Rosario PW,
Mourao GF, dos Santos JB, Calsolari MR 2014 Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin? Thyroid 24:533–536. 834. Leboulleux S, El Bez I, I, Borget I, Elleuch M, De ´andreis D, Al Ghuzlan A, Chougnet C, Bidault F, Mirghani H, Lumbroso J, Hartl D, Baudin E, Schlumberger M 2012 Postradioiodine treatment whole-body scan in the era of18-ﬂuorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid 22:832–838. 835. Wang PW, Wang ST, Liu RT, Chien WY, Tung SC, Lu YC, Chen HY, Lee CH 1999 Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 84:4549–4553. 836. Sugitani I, Fujimoto Y 2010 Does postoperative thyro- tropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial. J Clin Endocrinol Metab 95:4576–4583. 837. Klein Hesselink EN, Klein Hesselink MS, de
Bock GH, Gansevoort RT, Bakker SJ, Vredeveld EJ, van der Horst- Schrivers AN, van der Horst IC, Kamphuisen PW, Plukker JT, Links TP, Lefrandt JD 2013 Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 31:4046–4053.ATA THYROID NODULE/DTC GUIDELINES 123
838. Shargorodsky M, Serov S, Gavish D, Leibovitz E, Harpaz D, Zimlichman R 2006 Long-term thyrotropin- suppressive therapy with levothyroxine impairs small and large artery elasticity and increases left ventricular mass in patients with thyroid carcinoma. Thyroid 16:381–386. 839. Taillard V, Sardinoux M, Oudot C, Fesler P, Rugale C, Raingeard I, Renard E, Ribstein J, du CG 2011 Early detection of isolated left ventricular diastolic dysfunction in high-risk differentiated thyroid carcinoma patients on TSH-suppressive therapy. Clin Endocrinol (Oxf) 75: 709–714. 840. Leeper RD 1973 The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroidcarcinoma. J Clin Endocrinol Metab 36:1143–1152. 841. Beierwaltes WH, Nishiyama RH, Thompson NW, Copp JE, Kubo A 1982 Survival time and ‘‘cure’’ in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med 23:561–568. 842. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary
JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G 2001 Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 86:1568–1573. 843. Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW 2007 Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 110:1451–1456. 844. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: beneﬁts and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892– 2899. 845. Dupuy DE, Monchik JM, Decrea C, Pisharodi L 2001 Radiofrequency ablation of regional recurrence from well- differentiated thyroid malignancy. Surgery 130:971–977. 846. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR 2002
Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol 178:699–704. 847. Eustatia-Rutten CF, Romijn JA, Guijt MJ, Vielvoye GJ, van den Berg R, Corssmit EP, Pereira AM, Smit JW 2003 Outcome of palliative embolization of bone me-tastases in differentiated thyroid carcinoma. J Clin En- docrinol Metab 88:3184–3189. 848. Misra S, Meiyappan S, Heus L, Freeman J, Rotstein L, Brierley JD, Tsang RW, Rodin G, Ezzat S, Goldstein DP, Sawka AM 2013 Patients’ experiences following local- regional recurrence of thyroid cancer: a qualitative study. J Surg Oncol 108:47–51. 849. Robenshtok E, Fish S, Bach A, Dominguez JM, Shaha A, Tuttle RM 2012 Suspicious cervical lymph nodes de- tected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab 97:2706–2713. 850. Ito Y, Higashiyama T, Takamura Y, Kobayashi K, Miya A, Miyauchi
A 2011 Prognosis of patients with papillary thyroid carcinoma showing postoperative recurrence to the central neck. World J Surg 35:767–772. 851. Uchida H, Imai T, Kikumori T, Hayashi H, Sato S, Noda S, Idota A, Kiuchi T 2013 Long-term results of surgeryfor papillary thyroid carcinoma with local recurrence. Surg Today 43:848–853. 852. Newman KD, Black T, Heller G, Azizkhan RG, Hol- comb GW III, Sklar C, Vlamis V, Haase GM, La Quaglia MP 1998 Differentiated thyroid cancer: deter- minants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children’s Cancer Group. Ann Surg 227: 533–541. 853. Robie DK, Dinauer CW, Tuttle RM, Ward DT, Parry R, McClellan D, Svec R, Adair C, Francis G 1998 Theimpact of initial surgical management on outcome in young patients with differentiated thyroid cancer. J Pe-diatr Surg 33:1134–1138. 854. Chadwick D, Kinsman R, Walton
P 2012 The British Association of Endocrine and Thyroid Surgeons 2012. 4th edition. Dendrite Clinical Systems, Ltd, Oxfordshire, United Kingdom, pp 3–188. 855. Rosenthal MS, Angelos P, Cooper DS, Fassler C, Finder SG, Hays MT, Tendler B, Braunstein GD 2013 Clinical and professional ethics guidelines for the practice of thyroidology. Thyroid 23:1203–1210. 856. Yeh M, Bernet V, Ferris R, Loevner L, Mandel S, Orloff L, Randolph G, Steward D 2015 American Thyroid Association statement on preoperative imaging for thy- roid cancer surgery. Thyroid 25:3–14. 857. Tufano RP, Clayman G, Heller KS, Inabnet WB, Ke- bebew E, Shaha A, Steward DL, Tuttle RM 2014 Man- agement of recurrent/persistent nodal disease in patients with differentiated thyroid cancer: a critical review of the risks and beneﬁts of surgical intervention versus active surveillance. Thyroid 25:15–27. 858. Phelan E, Kamani D, Shin J, Randolph GW 2013 Neural monitored revision thyroid cancer surgery: surgical safety and
thyroglobulin response. Otolaryngol Head Neck Surg 149:47–52. 859. Urken ML, Milas M, Randolph GW, Tufano R, Bergman D, Bernet V, Brett EM, Brierley JD, Cobin R, Doherty G, Klopper J, Lee S, Machac J, Mechanick JI, Orloff LA, Ross D, Smallridge RC, Terris DJ, Clain JB, Tuttle M 2015 A review of the management of recurrent and persistent metastatic lymph nodes in well differentiated thyroid cancer: a multifactorial decision making guide created for the Thyroid Cancer Care Collaborative. Head Neck 37:605–614. 860. Merdad M, Eskander A, Kroeker T, Freeman JL 2012 Predictors of level II and Vb neck disease in metastatic papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 138:1030–1033. 861. Eskander A, Merdad M, Freeman JL, Witterick IJ 2013 Pattern of spread to the lateral neck in metastatic well- differentiated thyroid cancer: a systematic review and meta-analysis. Thyroid 23:583–592. 862. Schuff KG 2011 Management of recurrent/persistent papillary thyroid carcinoma:
efﬁcacy of the surgical option. J Clin Endocrinol Metab 96:2038–2039. 863. McCoy KL, Yim JH, Tublin ME, Burmeister LA, Ogil- vie JB, Carty SE 2007 Same-day ultrasound guidance in reoperation for locally recurrent papillary thyroid cancer. Surgery 142:965–972. 864. Hughes DT, Laird AM, Miller BS, Gauger PG, Doherty GM 2012 Reoperative lymph node dissection for recur- rent papillary thyroid cancer and effect on serum thyro- globulin. Ann Surg Oncol 19:2951–2957.124 HAUGEN ET AL.
865. Roh JL, Kim JM, Park CI 2011 Central compartment reoperation for recurrent/persistent differentiated thyroid cancer: patterns of recurrence, morbidity, and prediction of postoperative hypocalcemia. Ann Surg Oncol 18:1312–1318. 866. Shaha AR 2012 Recurrent differentiated thyroid cancer. Endocr Pract 18:600–603. 867. Palme CE, Waseem Z, Raza SN, Eski S, Walﬁsh P, Freeman JL 2004 Management and outcome of recurrent well-differentiated thyroid carcinoma. Arch Otolaryngol Head Neck Surg 130:819–824. 868. Clayman GL, Agarwal G, Edeiken BS, Waguespack SG, Roberts DB, Sherman SI 2011 Long-term outcome ofcomprehensive central compartment dissection in pa- tients with recurrent/persistent papillary thyroid carci- noma. Thyroid 21:1309–1316. 869. Clayman GL, Shellenberger TD, Ginsberg LE, Edeiken BS, El-Naggar AK, Sellin RV, Waguespack SG, Roberts DB, Mishra A, Sherman SI 2009 Approach and safety of comprehensive central compartment dissection in pa- tients with recurrent papillary thyroid carcinoma. Head Neck 31:1152–1163. 870. Chao TC, Jeng LB, Lin JD, Chen MF 1997
Reoperative thyroid surgery. World J Surg 21:644–647. 871. Erbil Y, Sari S, Agcaoglu O, Ersoz F, Bayraktar A, Salmaslioglu A, Gozkun O, Adalet I, Ozarmagan S 2010 Radio-guided excision of metastatic lymph nodes in thyroid carcinoma: a safe technique for previously operated neck compartments. World J Surg 34:2581– 2588. 872. Alzahrani AS, Raef H, Sultan A, Al Sobhi S, In- gemansson S, Ahmed M, Al Mahfouz A 2002 Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer. J Endocrinol Invest 25:526–531. 873. Travagli JP, Cailleux AF, Ricard M, Baudin E, Caillou B, Parmentier C, Schlumberger M 1998 Combination of radioiodine (131I) and probe-guided surgery for persis- tent or recurrent thyroid carcinoma. J Clin Endocrinol Metab 83:2675–2680. 874. Lee L, Steward DL 2008 Sonographically-directed neck dissection for recurrent thyroid carcinoma. Laryngo- scope 118:991–994. 875. Steward
DL 2012 Update in utility of secondary node dissection for papillary thyroid cancer. J Clin EndocrinolMetab 97:3393–3398. 876. Rubello D, Salvatori M, Casara D, Piotto A, Toniato A, Gross MD, Al-Nahhas A, Muzzio PC, Pelizzo MR 2007 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer. Eur J Surg Oncol 33:902–906. 877. Deleted. 878. Heilo A, Sigstad E, Fagerlid KH, Haskjold OI, Groholt KK, Berner A, Bjoro T, Jorgensen LH 2011 Efﬁcacy of ultrasound-guided percutaneous ethanol injection treat- ment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. J Clin Endocrinol Metab 96:2750–2755. 879. Hay ID, Lee RA, Davidge-Pitts C, Reading CC, Char- boneau JW 2013 Long-term outcome of ultrasound- guided percutaneous ethanol ablation of selected ‘‘re- current’’ neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previouslytreated by surgery and 131I therapy. Surgery 154:1448– 1454. 880. Guenette
JP, Monchik JM, Dupuy DE 2013 Image- guided ablation of postsurgical locoregional recurrence of biopsy-proven well-differentiated thyroid carcinoma. J Vasc Interv Radiol 24:672–679. 881. Park KW, Shin JH, Han BK, Ko EY, Chung JH 2011 Inoperable symptomatic recurrent thyroid cancers: pre- liminary result of radiofrequency ablation. Ann Surg Oncol 18:2564–2568. 882. Baek JH, Kim YS, Sung JY, Choi H, Lee JH 2011 Lo- coregional control of metastatic well-differentiated thyroid cancer by ultrasound-guided radiofrequency ab-lation. AJR Am J Roentgenol 197:W331-W336. 883. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE 2006 Radiofrequency ablation and percutaneous ethanol injec- tion treatment for recurrent local and distant well- differentiated thyroid carcinoma. Ann Surg 244:296–304. 884. Shin JE, Baek JH, Lee JH 2013 Radiofrequency and ethanol ablation for the treatment of recurrent thyroid cancers: current status and challenges. Curr Opin Oncol 25:14–19. 885. Na DG, Lee JH, Jung SL, Kim JH, Sung JY, Shin JH, Kim
EK, Lee JH, Kim DW, Park JS, Kim KS, Baek SM, Lee Y, Chong S, Sim JS, Huh JY, Bae JI, Kim KT, Han SY, Bae MY, Kim YS, Baek JH 2012 Radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: consensus statement and recommendations. Korean J Radiol 13:117–125. 886. Papini E, Bizzarri G, Bianchini A, Valle D, Misischi I, Guglielmi R, Salvatori M, Solbiati L, Crescenzi A, Pa- cella CM, Gharib H 2013 Percutaneous ultrasound- guided laser ablation is effective for treating selected nodal metastases in papillary thyroid cancer. J Clin En- docrinol Metab 98:E92–E97. 887. Sabra MM, Grewal RK, Tala H, Larson SM, Tuttle RM 2012 Clinical outcomes following empiric radioiodine therapy in patients with structurally identiﬁable meta- static follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans. Thyroid 22:877–883. 888. Schwartz DL, Lobo MJ, Ang KK, Morrison WH, Ro- senthal DI, Ahamad
A, Evans DB, Clayman G, Sherman SI, Garden AS 2009 Postoperative external beam radio- therapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat OncolBiol Phys 74:1083–1091. 889. Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY 2014 External beam radiotherapy with or without con- current chemotherapy in advanced or recurrent non- anaplastic non-medullary thyroid cancer. J Surg Oncol 110:375–382. 890. Ge JH, Zhao RL, Hu JL, Zhou WA 2004 Surgical treatment of advanced thyroid carcinoma with aero- digestive invasion. Zhonghua Er Bi Yan Hou Ke Za Zhi 39:237–240. (In Chinese.) 891. Avenia N, Ragusa M, Monacelli M, Calzolari F, Daddi N, Di CL, Semeraro A, Puma F 2004 Locally advanced thyroid cancer: therapeutic options. Chir Ital 56:501– 508. 892. McCaffrey JC 2000 Evaluation and treatment of aero- digestive tract invasion by well-differentiated thyroid carcinoma.
Cancer Control 7:246–252.ATA THYROID NODULE/DTC GUIDELINES 125
893. Musholt TJ, Musholt PB, Behrend M, Raab R, Scheu- mann GF, Klempnauer J 1999 Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon. Sur- gery 126:1078–1087. 894. Czaja JM, McCaffrey TV 1997 The surgical manage- ment of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 123:484–490. 895. Haymart MR, Muenz DG, Stewart AK, Griggs JJ, Banerjee M 2013 Disease severity and radioactive iodine use for thyroid cancer. J Clin Endocrinol Metab 98:678– 686. 896. Van Nostrand D 2009 The beneﬁts and risks of I-131 therapy in patients with well-differentiated thyroid can- cer. Thyroid 19:1381–1391. 897. Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, Togashi K, Itasaka S, Hiraoka M, Misaki T, Konishi J 2011 Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic dif- ferentiated thyroid carcinoma: a retrospective statistical
analysis of 198 cases. J Nucl Med 52:683–689. 898. Yim JH, Kim WB, Kim EY, Kim WG, Kim TY, Ryu JS, Moon DH, Sung TY, Yoon JH, Kim SC, Hong SJ, Shong YK 2011 Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation. J Clin Endocrinol Metab 96:3695–3700. 899. Van Nostrand D, Wartofsky L 2007 Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am 36:807–822, vii–viii. 900. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L 2002 Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid car- cinoma. Thyroid 12:121–134. 901. Chiesa C, Castellani MR, Vellani C, Orunesu E, Negri A, Azzeroni R, Botta F, Maccauro M, Aliberti G, Seregni E, Lassmann M, Bombardieri E 2009 Individualized do- simetry in the management of metastatic differentiated thyroid cancer. Q
J Nucl Med Mol Imaging 53:546–561. 902. Lassmann M, Reiners C, Luster M 2010 Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer 17:R161-R172. 903. Verburg FA, Hanscheid H, Biko J, Hategan MC, Lass- mann M, Kreissl MC, Reiners C, Luster M 2010Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 37:896–903. 904. Lassmann M, Hanscheid H, Chiesa C, Hindorf C, Flux G, Luster M 2008 EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in dif- ferentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405–1412. 905. Robbins RJ, Schlumberger MJ 2005 The evolving role of (131)I for the treatment of differentiated thyroid carci- noma. J Nucl Med 46 Suppl 1: 28S-37S. 906. Van Nostrand D, Atkins F, Moreau S, Aiken M, Kulkarni K, Wu JS, Burman
KD, Wartofsky L 2009 Utility of the radioiodine whole-body retention at 48 hours for modi- fying empiric activity of 131-iodine for the treatment of metastatic well-differentiated thyroid carcinoma. Thy- roid19:1093–1098.907. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA 2003 Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thy- roid cancer: largest safe dose using a risk-adapted ap- proach. J Nucl Med 44:451–456. 908. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL 1983 Relation be- tween effective radiation dose and outcome of radio- iodine therapy for thyroid cancer. N Engl J Med 309: 937–941. 909. Thomas SR, Maxon HR, Kereiakes JG 1976 In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 03:253–255. 910. Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J 2005 Radioiodine therapy for thyroid cancer and hy- perthyroidism in patients with end-stage renal

Subsets and Splits